References
1. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology. 2008;26(5):778-785.
2. Volders J, Haloua M, Krekel N, et al. Neoadjuvant chemotherapy in breast-conserving surgery–Consequences on margin status and excision volumes: a nationwide pathology study.European Journal of Surgical Oncology (EJSO). 2016;42(7):986-993.
3. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.International Journal of Radiation Oncology* Biology* Physics.2014;88(3):553-564.
4. Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer.Surgical oncology clinics of North America. 2018;27(1):95-120.
5. Myers DJ, Walls AL. Atypical Breast Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2021, StatPearls Publishing LLC.; 2021.
6. Worsham MJ, Abrams J, Raju U, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. The breast journal. 2007;13(2):115-121.
7. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. New England Journal of Medicine.2015;372(1):78-89.
8. Fowble B, Hanlon A, Patchefsky A, et al. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. International Journal of Radiation Oncology* Biology* Physics. 1998;42(1):105-115.
9. Goldstein NS, Lacerna M, Vicini F. Cancerization of lobules and atypical ductal hyperplasia adjacent to ductal carcinoma in situ of the breast: significance for breast-conserving therapy. American journal of clinical pathology. 1998;110(3):357-367.
10. Arora S, Menes TS, Moung C, Nagi C, Bleiweiss I, Jaffer S. Atypical ductal hyperplasia at margin of breast biopsy—is re-excision indicated? Annals of surgical oncology. 2008;15(3):843-847.
11. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer. 1994;73(1):118-124.
12. Li S, Liu J, Yang Y, et al. Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer. Journal of cancer research and clinical oncology. 2014;140(4):599-605.
13. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of pathology & laboratory medicine.2010;134(7):e48-e72.
14. Chen K, Zeng Y, Jia H, et al. Clinical outcomes of breast-conserving surgery in patients using a modified method for cavity margin assessment. Annals of surgical oncology. 2012;19(11):3386-3394.
15. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human pathology. 1992;23(10):1095-1097.
16. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627-633.
17. Tozbikian G, Brogi E, Vallejo CE, et al. Atypical ductal hyperplasia bordering on ductal carcinoma in situ: interobserver variability and outcomes in 105 cases.International journal of surgical pathology. 2017;25(2):100-107.
18. Simpson JF. Update on atypical epithelial hyperplasia and ductal carcinoma in situ. Pathology.2009;41(1):36-39.
19. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of tis, T1–2 breast carcinomas implications for clinical trials of breast‐conserving surgery.Cancer. 1985;56(5):979-990.
20. Recht A, Silen W, Schnitt SJ, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. International Journal of Radiation Oncology* Biology* Physics. 1988;15(2):255-261.
21. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast‐conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer.1989;63(10):1912-1917.
22. DiPaola RS, Orel SG, Fowble BL. Ipsilateral breast tumor recurrence following conservative surgery and radiation therapy. Oncology (Williston Park, NY).1994;8(12):59-68; discussion 71, 75.
23. Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Annals of surgical oncology.2016;23(3):749-756.
24. Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.Cancer Prevention Research. 2014;7(2):211-217.
25. Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy.JAMA oncology. 2017;3(1):36-41.
26. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute.2005;97(22):1652-1662.
27. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study. cancer. 1985;55(11):2698-2708.
28. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research.2008;14(24):8019-8026.
29. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet.2014;384(9938):164-172.
30. Cho DH, Bae SY, You JY, et al. Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer. The Kaohsiung journal of medical sciences. 2018;34(6):341-347.
31. van Nijnatten TJ, Simons J, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast cancer research and treatment. 2017;163(1):159-166.
32. Choi J, Laws A, Hu J, Barry W, Golshan M, King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol. 2018;25(12):3541-3547.